ObjectivesTo evaluate the safety and efficacy of high-dose dual therapy (HDDT) for Helicobacter pylori (H. pylori) eradication in patients with varying degrees of metabolic associated fatty liver disease (MAFLD)MethodsA total of 91 patients diagnosed with MAFLD complicated by H. pylori infection at the Department of Gastroenterology, Beijing Jishuitan Hospital, Capital Medical University, from October 2024 to December 2025, were enrolled. Based on liver transient elastography (FibroTouch) result